| Item Type | Name |
|
Concept
|
Gastrointestinal Agents
|
|
Academic Article
|
Cyclosporin for severe ulcerative colitis: a user's guide.
|
|
Academic Article
|
Comparative tolerability of treatments for inflammatory bowel disease.
|
|
Academic Article
|
Infliximab in Crohn's disease: first anniversary clinical experience.
|
|
Academic Article
|
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.
|
|
Academic Article
|
Evolutionary biologic therapy for inflammatory bowel disease.
|
|
Academic Article
|
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies.
|
|
Academic Article
|
Immunogenicity of infliximab in Crohn's disease.
|
|
Academic Article
|
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
|
|
Academic Article
|
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
|
|
Academic Article
|
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
|
|
Academic Article
|
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
|
|
Academic Article
|
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
|
|
Academic Article
|
Safety first: messages from Digestive Disease Week 2006.
|
|
Academic Article
|
Emerging biologic therapies in inflammatory bowel disease.
|
|
Academic Article
|
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
|
|
Academic Article
|
Moving ahead or falling behind?
|
|
Academic Article
|
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
|
|
Academic Article
|
Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
|
|
Academic Article
|
Controversies with aminosalicylates in inflammatory bowel disease.
|
|
Academic Article
|
Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
|
|
Academic Article
|
Management of Crohn's disease in adults.
|
|
Academic Article
|
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
|
|
Academic Article
|
General principles and pharmacology of biologics in inflammatory bowel disease.
|
|
Academic Article
|
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
|
|
Academic Article
|
European evidence-based consensus on the diagnosis and management of Crohn's disease.
|
|
Academic Article
|
The expanding role of biologic therapy for IBD.
|
|
Academic Article
|
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
|
|
Academic Article
|
An evidence-based systematic review on medical therapies for inflammatory bowel disease.
|
|
Academic Article
|
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.
|
|
Academic Article
|
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
|
|
Academic Article
|
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
|
|
Academic Article
|
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
|
|
Academic Article
|
Practical application of anti-TNF therapy for luminal Crohn's disease.
|
|
Academic Article
|
What to take from TREAT?
|
|
Academic Article
|
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
|
|
Academic Article
|
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
|
|
Academic Article
|
Review article: safety of infliximab in clinical trials.
|
|
Academic Article
|
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
|
|
Academic Article
|
Infliximab or cyclosporine for severe ulcerative colitis.
|
|
Academic Article
|
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies.
|
|
Academic Article
|
AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mild-to-moderate Crohn's disease: FHAST-1, a phase 3, multicenter, placebo-controlled study.
|
|
Academic Article
|
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
|
|
Academic Article
|
Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.
|
|
Academic Article
|
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
|
|
Academic Article
|
Aminosalicylates for induction of remission or response in Crohn's disease.
|
|
Academic Article
|
Optimizing pharmacologic management of inflammatory bowel disease.
|
|
Academic Article
|
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.
|
|
Academic Article
|
Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
|
|
Academic Article
|
Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?
|
|
Academic Article
|
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.
|
|
Academic Article
|
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
|
|
Academic Article
|
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY).
|